J. Bremer

[Botulinum toxin for the treatment of neurogenic detrusor hyperactivity. Consensus paper on use for neurogenic bladder dysfunction].

J. Pannek, B. Wefer, C. Seif, 2007, Der Urologe. Ausg. A.

Bladder management, severity of injury and period of latency: a descriptive study on 135 patients with spinal cord injury and bladder cancer

K. Golka, R. Thietje, R. Kirschner-Hermanns, 2021, Spinal Cord.

Predominant symptoms in irritable bowel syndrome correlate with specific autonomic nervous system abnormalities.

T. Abell, T. Cutts, B. Familoni, 1994, Gastroenterology.

Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX®) therapy in Germany

J. Pannek, B. Wefer, C. Seif, 2010, World Journal of Urology.

The Real Daily Need for Incontinence Aids and Appliances in Patients with Neurogenic Bladder Dysfunction in a Community Setting in Germany

K. Golka, R. Thietje, C. Tiburtius, 2020, Journal of multidisciplinary healthcare.

Medizinische Qualitätsstandards ausgewählter urologischer Hilfsmittel

V. Geng, R. Böthig, A. Kaufmann, 2018, Der Urologe.

Aktuelles zu neurogenen Dysfunktionen des unteren Harntraktes bei Multipler Sklerose

W. Feneberg, R. Kirschner-Hermanns, P. Schmidt, 2021, Der Nervenarzt.